Carol Austin, Associate Director of Discovery, who managed the project, said ‘Selcia’s unique expertise in the area of peptidyl prolyl isomerase screening and medicinal chemistry enabled Cypralis to achieve the milestones for this challenging project. We look forward to continuing to support Cypralis in achieving the goals of the Innovate UK Early Stage award’.

Cypralis issued this press release on 23^rd January 2017; follow this link for the full version: